tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SE:ONCO Stock Latest News

Oncopeptides AB Balances Growth, Cash Crunch in Earnings
Company AnnouncementsOncopeptides AB Balances Growth, Cash Crunch in Earnings
4d ago
Oncopeptides launches SEK 200m rights issue to fund Pepaxti rollout and glioblastoma push
PremiumCompany Announcements
Oncopeptides launches SEK 200m rights issue to fund Pepaxti rollout and glioblastoma push
5d ago
Oncopeptides Doubles 2025 Sales and Raises Capital to Drive Glioblastoma Push
PremiumCompany Announcements
Oncopeptides Doubles 2025 Sales and Raises Capital to Drive Glioblastoma Push
5d ago
Oncopeptides Sets Date for 2025 Year-End Results Presentation
PremiumCompany Announcements
Oncopeptides Sets Date for 2025 Year-End Results Presentation
11d ago
Oncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027
PremiumCompany Announcements
Oncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027
1M ago
Oncopeptides Drug Pepaxti Shows Strong Efficacy in High-Risk Multiple Myeloma
PremiumCompany AnnouncementsOncopeptides Drug Pepaxti Shows Strong Efficacy in High-Risk Multiple Myeloma
2M ago
Oncopeptides AB Establishes Nomination Committee for 2026 AGM
Premium
Company Announcements
Oncopeptides AB Establishes Nomination Committee for 2026 AGM
3M ago
Expert Panel Endorses Oncopeptides’ Pepaxti for Myeloma Treatment
Premium
Company Announcements
Expert Panel Endorses Oncopeptides’ Pepaxti for Myeloma Treatment
3M ago
Oncopeptides AB Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
Oncopeptides AB Earnings Call Highlights Growth and Challenges
4M ago
Oncopeptides AB Reports Strong Q3 2025 Growth and Strategic Milestones
PremiumCompany Announcements
Oncopeptides AB Reports Strong Q3 2025 Growth and Strategic Milestones
4M ago
Oncopeptides’ NK Cell Engager Study to be Presented at ASH
PremiumCompany Announcements
Oncopeptides’ NK Cell Engager Study to be Presented at ASH
4M ago
Oncopeptides Adjusts Share Structure Amid Strategic Incentive Program
PremiumCompany Announcements
Oncopeptides Adjusts Share Structure Amid Strategic Incentive Program
4M ago
Oncopeptides to Release Q3 2025 Financial Report
PremiumCompany AnnouncementsOncopeptides to Release Q3 2025 Financial Report
4M ago
Oncopeptides to Host Strategic Capital Markets Update
Premium
Company Announcements
Oncopeptides to Host Strategic Capital Markets Update
4M ago
Oncopeptides’ Pepaxti Shows Promising Long-term Results in Myeloma Treatment
Premium
Company Announcements
Oncopeptides’ Pepaxti Shows Promising Long-term Results in Myeloma Treatment
4M ago
Oncopeptides Issues Warrants to Meet EIB Loan Obligations
PremiumCompany Announcements
Oncopeptides Issues Warrants to Meet EIB Loan Obligations
4M ago
Oncopeptides AB Announces Share and Vote Changes Post Rights Issue
PremiumCompany Announcements
Oncopeptides AB Announces Share and Vote Changes Post Rights Issue
5M ago
Oncopeptides AB’s Rights Issue Oversubscribed, Raising SEK 150 Million
PremiumCompany Announcements
Oncopeptides AB’s Rights Issue Oversubscribed, Raising SEK 150 Million
5M ago
Oncopeptides’ Pepaxti Shows Promising Real-World Efficacy and Safety
PremiumCompany Announcements
Oncopeptides’ Pepaxti Shows Promising Real-World Efficacy and Safety
6M ago
Oncopeptides AB Announces SEK 150 Million Rights Issue
PremiumCompany AnnouncementsOncopeptides AB Announces SEK 150 Million Rights Issue
6M ago
Oncopeptides AB Announces SEK 150 Million Rights Issue and Progress in Japanese Partnership
Premium
Company Announcements
Oncopeptides AB Announces SEK 150 Million Rights Issue and Progress in Japanese Partnership
6M ago
Oncopeptides Reports Strong Q2 2025 Growth and Strategic Advances
Premium
Company Announcements
Oncopeptides Reports Strong Q2 2025 Growth and Strategic Advances
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >